COVID-19 vaccine update

Dec 9, 2020 | Jennifer O'Hara | @jenohara

a-healthcare-worker-with-blue-gloves-PPE-holding-a-test-tube-and-vaccine-syringe-16x9-1-1536x864

Last week, the first COVID-19 vaccine was approved for emergency authorization use in the United Kingdom. Meanwhile in the U.S., plans are being made to distribute COVID-19 vaccines, pending approval by the Food and Drug Administration.

The Advisory Committee on Immunization Practices, a committee within the Centers for Disease Control and Prevention, recommends that health care workers and elderly people living in long-term care facilities receive top priority for COVID-19 vaccination in the U.S.

On the Mayo Clinic Q&A podcast, Dr. Gregory Poland, an infectious diseases expert and head of Mayo Clinic's Vaccine Research Group, gives an update on vaccine approval and discusses logistics COVID-19 vaccine distribution.

To practice safe social distancing during the COVID-19 pandemic, this interview was conducted using video conferencing. The sound and video quality are representative of the technology used. For the safety of its patients, staff and visitors, Mayo Clinic has strict masking policies in place. Anyone shown without a mask was recorded prior to COVID-19 or recorded in an area not designated for patient care, where social distancing and other safety protocols were followed.

Connect with others talking about the pandemic and supporting one another in the COVID-19 support group.

Information in this post was accurate at the time of its posting. Due to the fluid nature of the COVID-19 pandemic, scientific understanding, along with guidelines and recommendations, may have changed since the original publication date.

For more information and all your COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.

Dr. Poland has served as a consultant for Merck & Co. Inc., Medicago Inc., GlaxoSmithKline plc, Sanofi Pasteur, Emergent BioSolutions Inc., Dynavax Technologies Corp., Genentech Inc., Eli Lilly and Co., Kentucky BioProcessing Inc. and Genevant Sciences Corp., and Janssen Pharmaceuticals Inc. He is a paid scientific adviser for Johnson & Johnson. Honoraria: Elsevier.

 

 

Please sign in or register to post a reply.